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NMDA receptors are ligand-gated ion channels that
mediate excitatory synaptic transmission in the cen-
tral nervous system. Partial agonists elicit submaxi-
mal channel activation, but crystal structures of the
ligand-binding domains (LBDs) bound with partial
and full agonists show little difference. To uncover
the molecular mechanism for partial agonism, here
we computed the free-energy surfaces of the GluN1
(an obligatory subunit of NMDA receptors) LBD
bound with a variety of ligands. The free-energy
minima are similarly positioned for full and partial ag-
onists, but the curvatures are significantly reduced in
the latter case, indicatinghigherprobabilities for sam-
pling conformations with a not fully closed domain
cleft. The free-energy surfaces for antagonists have
both shifted minima and further reduced curvatures.
Reduced curvature of free-energy surface appears
to explainwell the partial agonismatNMDA receptors
and may present a unique paradigm in producing
graded responses for receptors in general.
INTRODUCTION
Ionotropic glutamate receptors (iGluRs) are a family of ligand-
gated tetrameric ion channels that convert chemical signals
carried by neurotransmitters into excitatory electrical signals
(Traynelis et al., 2010). The three major subtypes of this family,
i.e., AMPA, NMDA, and kainite receptors, share a common
modular architecture, including an amino-terminal domain
(ATD), a ligand-binding domain (LBD), and a transmembrane
domain (TMD) (Karakas and Furukawa, 2014; Lee et al., 2014;
Sobolevsky et al., 2009). NMDA receptors are heteromeric as-
semblies composed of two obligatory GluN1 subunits and two
GluN2/N3 subunits, and require simultaneous binding of glycine
and glutamate/glycine for activation (Johnson and Ascher,
1987). The LBD can be further divided into the D1 and D2 lobes
and is reminiscent of a clamshell, with the ligand-binding site sit-
uated within the cleft (Armstrong et al., 1998). Agonist binding in-
duces cleft closure, whose effect is transmitted by LBD-TMD
linkers to open the channel pore (Dai and Zhou, 2013; Dong
and Zhou, 2011; Kazi et al., 2014).228 Structure 23, 228–236, January 6, 2015 ª2015 Elsevier Ltd All rigFull agonists elicit maximal channel activation whereas antag-
onists inhibit channel activation. In comparison, partial agonists
possess submaximal efficacy, and thereby provide a unique
perspective into the link between ligand-induced conformational
change and channel activation (Inanobe et al., 2005). Clinically,
GluN1-binding partial agonists, such as D-cycloserine and
GLYX-13, have emerged as promising drug leads to treat neuro-
logical diseases. D-cycloserine was used to facilitate extinction
of fear (Ressler et al., 2004) and augment therapy for social anx-
iety disorder (Hofmann et al., 2006). GLYX-13was shown to have
antidepressant effects without the side effects found for keta-
mine, a channel blocker (Burgdorf et al., 2013). Therefore, it is
of great interest to understand the molecular mechanism under-
lying the partial agonism at NMDA receptors.
Partial agonists for AMPA receptors induce graded LBD cleft
closure in crystal structures, correlating with submaximal chan-
nel activation (Armstrong andGouaux, 2000; Du¨rr et al., 2014; Jin
et al., 2003). In contrast, for NMDA receptors, a correlation be-
tween the degree of cleft closure and agonist efficacy was not
observed: structures of GluN1-3 LBDs bound with their respec-
tive full and partial agonists show essentially the same degrees
of cleft closure (Furukawa and Gouaux, 2003; Hansen et al.,
2013; Inanobe et al., 2005; Vance et al., 2011; Yao et al.,
2008). Crystallography has thus not yielded an explanation for
the partial agonism at NMDA receptors. Corresponding results
for kainate receptors appear mixed. Earlier structures of
GluK1-2 LBDs bound with full agonists, partial agonists, and
an antagonist suggested a correlation between cleft closure
and agonist efficacy (Hald et al., 2007; Mayer, 2005; Nanao
et al., 2005; Naur et al., 2005), but more recently a weak partial
agonist was found to induce full cleft closure in the GluK1 LBD
(Frydenvang et al., 2009).
In addition to the degree of cleft closure, several lines of evi-
dence suggest that the stability of LBD cleft closure also con-
tributes to partial agonism at AMPA receptors. For example,
mutations that disrupted an interlobe hydrogen bond in GluA2
decreased both agonist affinity and efficacy (Robert et al.,
2005). NMR data indicated that, compared to partial agonists
with high efficacies, those with low efficacies induced a less sta-
ble cleft closure of the GluA2 LBD (Ahmed et al., 2013; Maltsev
et al., 2008). According to single-molecule fluorescence reso-
nance-energy-transfer experiments on the GluA2 LBD in com-
plex with several partial agonists, the fraction of time that the
LBD spent in cleft-closed conformations correlated with the
extent of channel activation (Ramaswamy et al., 2012). Molecu-
lar dynamics simulations also have presented evidence ofhts reserved
Figure 1. Anticorrelation between Ligand
Size and Efficacy
(A) Chemical structures of seven GluN1 ligands.
Full agonists, Gly and DSN; partial agonists, DCS,
ACPC, and ACBC; antagonists, CLE and DCKA.
(B) A plot of the relative efficacies of the ligands
(Traynelis et al., 2010) against their volumes.
Linear regression (red line) on the data for six li-
gands (other than DCKA) has R2 = 0.72. DSN is
less compact than DCS but its hydroxyl can
hydrogen bond with the LBD, thereby stabilizing
the cleft-closed structure.
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Free-Energy Surface and Partial Agonismconformational flexibility associated with partial-agonist binding
(Arinaminpathy et al., 2006; Postila et al., 2011).
A mechanistic model that bridges the gap between structural
and functional studies and convincingly explains the partial ago-
nism at NMDA receptors is still missing, although some factors
have been put forward as potential determinants. In particular,
the interaction between LBD and ATD was thought to regulate
agonist efficacy and channel gating (Dravid et al., 2010; Hansen
et al., 2013; Yuan et al., 2009). However, ATD is not an indispen-
sible component for channel gating, as removal of ATD from
NMDA receptors had only minor effects (Yuan et al., 2009),
similar to observations on ATD-removed AMPA and kainate re-
ceptors (Pasternack et al., 2002; Plested and Mayer, 2007).
Given the absence of graded cleft closure in the LBD structures,
motion in an orthogonal direction, i.e., the interlobe relative twist
around an axis along the domain hinge, was proposed as an
alternative cause of partial agonism (Birdsey-Benson et al.,
2010; Bjerrum and Biggin, 2008), even though such a twist is
hardly detectable in the crystal structures. Based on steeredmo-
lecular dynamics simulations, it was also suggested that a par-
tial-agonist-bound GluN1 LBD was not as firmly closed as a
full-agonist-bound counterpart (Ylilauri and Pentika¨inen, 2012).
Whereas crystal structures represent single conformations,
likely corresponding to free-energy minima, during channel
gating the LBDmust traverse a range of conformations, dictated
by the free-energy surface. The free energies generated by
GluA2 LBD cleft closure upon binding a variety of ligands have
been calculated (Lau and Roux, 2007, 2011). Very recently, cal-
culations of free-energy surfaces for apo and full-agonist-bound
GluN1-3 LBDs were used to characterize their conformational
spaces (Yao et al., 2013).
To uncover the molecular mechanism underlying partial ago-
nism at NMDA receptors, here we calculated the free-energy
surfaces of the GluN1 LBD bound with various ligands, including
two full agonists, three partial agonists, and two antagonists. For
the full and partial agonists, the positions of the free-energy
minima were in close proximity, in line with the crystal structures.
However, the curvatures of the free-energy basins were dif-
ferent: those for the full agonists were steep, whereas for partial
agonists with increasingly larger sizes and lower efficacies, the
curvatures were progressively reduced. The free-energy sur-
faces for antagonists had both shifted minima and even broader
basins. The reduced curvatures indicated weakened interlobe
interactions and gave rise to higher probabilities of opening the
LBD cleft, thereby leading to reduced agonist efficacy. A poten-
tial curvature determinant was Asp732 on the D2 lobe, which, inStructure 23, 22response to increasing ligand size, became more likely to adopt
a second rotamer, leading to weakened interlobe interactions.
Reduced curvature of free-energy surface may present a unique
paradigm in producing graded responses for receptors in
general.
RESULTS
Apparent Anticorrelation between Ligand Size and
Efficacy
Seven GluN1-binding ligands were studied here (Figure 1A),
including two full agonists (glycine [Gly] and D-serine [DSN]),
three partial agonists (D-cycloserine [DCS], 1-aminocyclopro-
pane-1-carboxylic acid [ACPC], and 1-aminocyclobutane-1-
carboxylic acid [ACBC]), and two antagonists (1-aminocyclo-
pentane-1-carboxylic acid [CLE] and 5,7-dichlorokynurenic
acid [DCKA]). Previously, it was observed on both AMPA recep-
tors and acetylcholine receptors that an anticorrelation exists
between ligand size and efficacy (Du et al., 2012). The same
trend was also apparent for these GluN1-binding ligands (Fig-
ure 1B). The full agonists were among the smallest in size, partial
agonists with decreasing efficacies had increasing sizes, and the
antagonists were the largest in size. Whereas the LBDs in AMPA
receptors apparently respond to ligand size through the degree
of cleft closure, the response of the GluN1 LBD was different,
as detailed below.
Free-Energy Surfaces of GluN1 LBD Bound with Full and
Partial Agonists Have Similar Minimum Positions
Our guiding hypothesis was that the free-energy landscape of
the GluN1 LBD is ligand dependent, and the resulting differ-
ence in conformational sampling may lead to differences in
the extent of channel activation. Since the two lobes of the
LBD are relatively rigid, it is likely that their relative motion is
functionally important. Following Lau and Roux (2007), we
used two interlobe distances, x1 and x2, to describe the relative
motion (Figure 2A). The free-energy surface over x1 and x2 for
each ligand-bound species was calculated via umbrella sam-
pling, specifically by running molecular dynamics simulations
with x1 and x2 harmonically restrained to 171 target values.
For the Gly-bound case, the initial conformations of these sim-
ulations were generated by a series of targeted molecular dy-
namics simulations, starting from the crystal structure (Protein
Data Bank [PDB] entry 1PB7). The resulting free-energy sur-
face, combining data over a total simulation time of 513 ns, is
shown in Figure 2B.8–236, January 6, 2015 ª2015 Elsevier Ltd All rights reserved 229
Figure 2. Reaction Coordinates and the
Free-Energy Surface of the Gly-Bound
GluN1 LBD
(A) Two interlobe distances, x1 and x2, were
defined to describe the relative motion between
the lobes. The view is directly into the domain cleft,
with D1 in green and D2 in cyan.
(B) Free-energy surface of the Gly-bound GluN1
LBD, presented as contours. The free-energy
minimum is highlighted by a white dot. Also shown
are x1c and x2c values calculated on the crystal
structures of the LBD bound with three ligands as
follows: Gly, white star (PDB 1PB7); CLE, gray star
(PDB 1Y1M); and DCKA, black star (PDB 1PBQ).
The x1
0 coordinate with x20 fixed at (x1 m – x2 m)/2 is
shown by a white line.
See also Table S1.
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in the Gly-bound case were used to seed simulations for the
next larger ligand (i.e., DCS). This procedure of replacing a
smaller ligand with the next larger one was repeated, resulting
in free-energy surfaces for the LBD bound with the six non-Gly
ligands (Figure S1 available online). As references, x1 and x2
values are also indicated over the free-energy surfaces (Fig-
ure 2B; Figure S1) for the crystal structures of the GluN1 LBD
bound with Gly, CLE, and DCKA.
The values of the two reaction coordinates at the free-energy
minima, denoted as x1 m and x2 m, are collected in Table S1.
These values were very similar for the five full and partial ago-
nists. Specifically, x1 m and x2 m values fell in the narrow ranges
of 8.65 to 9.05 A˚ and 8.45 to 8.65 A˚, respectively. This finding
is in line with the similarity of the crystal structures of these com-
plexes. In comparison, x1 m and x2 m were larger for the two
antagonists, especially for DKCA, also in line with the corre-
sponding crystal structures. The calculated minimum positions
were somewhat different from the values, x1c and x2c, for the cor-
responding crystal structures (Table S1), with slight overestima-
tion in x2 m for the full and partial agonists but underestimation in
x2 m for CLE. Such deviations have been seen in previous
computational studies (Lau and Roux, 2007; Yao et al., 2013),
and probably result from a combination of packing in the crystal
lattice and deficiency in the computation.
Reduced Curvature of Free-Energy SurfaceMay Explain
Submaximal Efficacy
Further insight into energetic differences arising from full- and
partial-agonist binding is gained by overlaying the free-energy
surface in the Gly-bound case to each of the other six free-en-
ergy surfaces (Figure 3A; all the surfaces were contoured to
8 kcal/mol above the free-energy minima). The free-energy con-
tours for the two agonists nearly overlapped, with the basin for
DSN only slightly broader. With the binding of the three partial
agonists (DCS, ACPC, and ACBC), there were slight increases
in x1 m, but, more prominently, the basins broadened progres-
sively as the ligand size increased. The reduced curvature in-
creases the probabilities of the LBD moving away from the
free-energy minima, i.e., to sample conformations with a not fully
closed cleft. For the two antagonists (CLE and DCKA), the out-230 Structure 23, 228–236, January 6, 2015 ª2015 Elsevier Ltd All rigward shifts of the minimum positions were accompanied by sig-
nificant broadening of the free-energy basins. Therefore, the
LBD has even higher probabilities of sampling open-cleft confor-
mations, as to be expected for antagonists.
The differences in free-energy basin curvature among the
various ligands can be seen more clearly when the free-energy
surfaces are sliced along a particular direction, specifically along
the new coordinate x1
0 = (x1 + x2)/2 when its orthogonal coordi-
nate x2
0 = (x1 – x2)/2 is fixed at (x1 m – x2 m)/2 (shown as a white
line in Figures 2B and S1). Again, for the two full agonists and
three partial agonists, the slices of the free-energy surfaces
showed only slight changes in minimum positions but progres-
sive reductions in curvature as the ligand size increased and
agonist efficacy decreased (Figure 3B). Therefore, even though
partial agonists can induce full LBD cleft closure as observed
in crystal structures, the likelihood, identified here, that the
LBD also samples cleft-open conformations leads to a reduced
extent of channel activation.
Ligand Size Influences LBD’s Propensity to Stay in
Cleft-Open Conformations
During the umbrella-sampling simulations, the LBD cleft was
forced to open by harmonic restraints on the interlobe distances
x1 and x2. Of course, each LBD-ligand complex was also under
the control of its intrinsic free-energy surface. The latter, as pre-
sented in Figure 3A, was obtained by removing the biasing ef-
fects of the harmonic restraints using the weighted histogram
analysis method (Kumar et al., 1992). We would like to gain
further physical insight into the free-energy surface, in particular
regarding potential causal link of its curvature to ligand size.
Although the umbrella-sampling simulations showed the com-
bined effects of the harmonic restraints and the intrinsic free-en-
ergy surface, one can in fact read off information on the latter’s
curvature directly from the umbrella-sampling simulations. This
is because when the free-energy surface rose sharply, the corre-
sponding strong intrinsic force would pull x1 and x2 toward the
free-energy minimum irrespective of the harmonic restraints. In
contrast, when the free-energy basin was shallow, such that
the intrinsic force to move toward the free-energy minimum
was weak, the x1 and x2 coordinates were likely to stay close
to their restraint values. Therefore, in the umbrella-samplinghts reserved
Figure 3. Comparison between Free-Energy Surfaces of the LBD Bound with Gly and Non-Gly Ligands
(A) Overlay of free-energy contours for the Gly-bound case (black) and the indicated non-Gly counterpart (red).
(B) Slices of the free-energy surfaces along x1
0 for the full and partial agonists (solid curves). The results for the two antagonists are shown as dashed curves for
reference.
See also Figure S1.
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Free-Energy Surface and Partial Agonismsimulations, a higher tendency to move toward the free-energy
minimum reflected a larger curvature of the free-energy surface,
whereas a lower tendency to move toward the free-energy min-
imum reflected a smaller curvature of the free-energy surface. By
comparing the distributions of x1 and x2 in the umbrella-sampling
simulations with varied ligands but the same harmonic restraints,
we can directly demonstrate differences in free-energy basin
curvature.
Based on the preceding reasoning and reinforcing the results
in Figure 3, the distributions of x1 and x2 indicate that the ten-
dency to stay in open-cleft conformations becomes higher as
the ligand size is increased (Figure 4A). For example, with the
cleft restrained partially open at (x1, x2) = (10.5, 10.5), the distribu-
tions of x1 and x2 in the Gly-bound case peaked at (10.0, 10.2), a
significant shift toward (x1 m, x2 m) that reflects a large curvature
of the free-energy surface. In comparison, the peak position at
(10.2, 10.2) in the ACBC-bound case was closer to the restraint
values, and, thus, reflected a higher tendency to maintain a
partially open cleft. The more open conformations sampled
when the LBDwas bound with the larger ligand can be illustrated
by a comparison of the last snapshots of the Gly- and ACBC-
bound simulations (Figure 4B). The emerging picture is that the
larger ACBC, similar to the even larger DCKA (an antagonist; Fig-
ure 4C), is better able to pry open the LBD cleft, apparently by
weakening D1-D2 interactions.
Asp732 Acts as a Switch for Regulating Interlobe
Interactions
Howdoes the LBD sense the change in ligand size? By analyzing
the hydrogen-bonding network around the bound ligand (Fig-
ure 5A), we identified a potential key residue (Asp732) in regu-
lating D1-D2 interactions, leading to modulation of the free-en-
ergy-surface curvature and, ultimately, the efficacy in channel
activation. Asp732 is the only residue on the D2 lobe that formsStructure 23, 22a hydrogen bond with the amino group of the full and partial ag-
onists in the crystal structures. In the simulations with the cleft
restrained partially open, the Asp732 side chain could switch
its hydrogen-bonding partner(s) from the ligand amino group to
the side chain of Gln536 on the domain hinge and/or the back-
bone amide of Ala734 on the D2 lobe (Figure 5B). The latter
two formed a hydrogen bond in the cleft-closed structures,
which was broken when either partner hydrogen bonded to
Asp732. The ligand-Asp732 and Gln536-Ala734 hydrogen
bonds appeared to contribute significantly to the stability of
the cleft-closed conformations. When the ligand size increased,
these hydrogen bonds were more and more likely replaced by
Asp732-Gln536 and Asp732-Ala734 hydrogen bonds (Fig-
ure 5C), thereby weakening interlobe interactions.
The switch in hydrogen-bonding partners was achieved
through a change in the side chain c1 torsion angle of Asp732:
the partner(s) was the ligand at c1 –60 but was Gln536/
Ala734 at c1 –180 (Figure 5B). There was an accompanying
180 flip of the Gln536 amide via a change in c2 + c3. In the sim-
ulations with the cleft restrained partially open, the probability for
Asp732 to adopt the –180 rotamer increased with increasing
ligand size (Figure 5D). Interestingly, the switch of hydrogen-
bonding partners through the change in rotamers and the influ-
ence of ligand size on the latter change, manifested in the
umbrella-sampling simulations, are also seen in GluN1–3 crystal
structures. In the structures of the GluN1 LBD bound with the
six smaller ligands, c1 is –60 and Asp732 hydrogen bonds
with the ligands, but in the structure with DCKA bound, c1 is
–180 and Asp732 hydrogen bonds with Ala734 and Val735.
In the apo GluN1 LBD structure (PDB 4KCC), Asp732 can adopt
both rotamers, and potentially forms hydrogen bonds with
Gln536 and Ala734 in the –180 rotamer. In the structure of the
Gly-bound GluN3A LBD (PDB 2RC7), c1 of the residue corre-
sponding to Asp732 is –60, just like in the GluN1 counterpart.8–236, January 6, 2015 ª2015 Elsevier Ltd All rights reserved 231
Figure 4. Influence of Ligand Size on the
Propensity of LBD to Stay Open
(A) Distributions of x1 and x2 for the LBD boundwith
Gly (gray curves) and ACBC (red curves) in um-
brella-sampling simulations with both x1 and x2
restrained at 10.5 A˚. The corresponding results
for DCKA are shown as dashed curves for refer-
ence. The restraint values are shown as vertical
lines.
(B) Comparison of the LBD bound with ACBC (red)
and Gly (gray) in the last snapshots of the um-
brella-sampling simulations. Superposition is
made on the Ca atoms of the six D1 residues used
for defining x1 and x2 (i.e., Leu517-Ile519 and
His404-Glu406).
(C) Corresponding results for the DCKA-bound
case are shown (orange) as reference.
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2A5S), a larger agonist, has the Asp732 counterpart adopting the
–180 rotamer and forming a hydrogen bond with the Val735
counterpart. It is perhaps no coincidence that the cleft openings
of the glutamate-bound GluN2 LBDs are larger than those of the
Gly-bound GluN1 andGluN3 LBDs (Figure S2). The crystal struc-
tures thus reinforce the finding of our simulations that GluN1
Asp732 can respond to the increase in ligand size by adopting
a second rotamer, leading to weakened interlobe interactions.
DISCUSSION
In this study, we computed the free-energy surfaces of theGluN1
LBD bound with a variety of ligands to bridge the gap between
structural and functional studies and uncover the molecular
mechanism for the partial mechanism at NMDA receptors.
When the LBD is boundwith full and partial agonists, the free-en-
ergy surfaces have similarly positioned minima, in line with crys-
tal structures, but the curvatures are progressively reduced as
the ligand size is increased and agonist efficacy is lowered.
The free-energy surfaces for antagonists have minima that are
shifted toward conformations with the LBD cleft more open as
well as curvatures that are further reduced. These results
demonstrate that not only theminimum position but also the cur-
vature of the free-energy surface of the ligand-bound LBD can be
a determinant for the efficacy in eliciting channel activation.
Our study highlights the free-energy basin curvature as a po-
tential determinant of partial agonism. Although one might be
tempted to make quantitative predictions on agonist efficacy
from the free-energy surfaces calculated here, one has to pro-
ceed with caution since doing so would involve assumptions
that are beyond what this study can justify. First, one has to as-232 Structure 23, 228–236, January 6, 2015 ª2015 Elsevier Ltd All rights reservedsume that the equilibrium population
fraction of the LBD in some active region
of the conformational space provides a
direct measure of agonist efficacy. Sec-
ond, one has to specify the boundary of
this active region. For the purpose of illus-
tration, let us assume that the active re-
gion is specified by x1 < 9 A˚ and x2 <
9 A˚. Then the active population fractionis given by the integration of the Boltzmann factor of the free en-
ergy W(x1, x2) in the active region divided by the corresponding
integration over the full conformational space. The resulting
active population fractions of the LBD are 0.77 for the agonist
Gly, 0.37 for the partial agonist ACBC, and 0.02 for the antago-
nist CLE. These differences in active population fraction confirm
the expectation that the ability of a partial agonist to induce LBD
active conformations is intermediate between those of a full
agonist and an antagonist. It is plausible that they are linked,
either directly or indirectly, to the differences in agonist efficacy.
However, we stress that, rather than making quantitative predic-
tions, the value of our study lies in presenting a molecular mech-
anistic explanation for partial agonism.
The free-energy surface defined here specifically probes the
energetic cost to open the LBD cleft. The stability of LBD closure
has been proposed, in addition to the degree of cleft closure, as
a contributor to partial agonism (Ahmed et al., 2013; Arinaminpa-
thy et al., 2006; Maltsev et al., 2008; Postila et al., 2011; Ram-
aswamy et al., 2012; Robert et al., 2005; Ylilauri and Pentika¨inen,
2012), especially at AMPA receptors. The curvature of the free-
energy basin highlighted in the present study provides a quanti-
tative measure of the cleft closure stability. We have shown that
the curvature is dictated by the strength of interlobe interactions,
and identified a potential key residue, Asp732, for regulating in-
terlobe interactions by a rotameric switch in response to the
increase in ligand size. This role of Asp732 appears to be sup-
ported by GluN1–3 crystal structures and can be further tested
by functional assays of mutants.
We further speculate that Asp732 might be involved in ligand
recognition during the binding process. In the apo form, the
side chain of Asp732 samples two rotameric states, with c1
around 60 and 180, respectively. When an agonist initially
Figure 5. Asp732 as a Potential KeyResidue
for Regulating D1-D2 Interactions
(A) The protein-ACPC complex in a snapshot from
an umbrella-sampling simulation, highlighting the
ligand and the surrounding residues (boxed).
Helix-I, on which Ala734 occupies an N-terminal
position, is shown as ribbon in magenta; b strand
10, which contains the hinge region, is shown in
cyan. In the simulation, both x1 and x2 were
restrained at 10.0 A˚.
(B) Two snapshots from this simulation. (Top)
Asp732 has c1 at 80 and hydrogen bonds with
the ligand, while Gln536 (with c2 + c3 = 153
) and
Ala734 also form a hydrogen bond. (Bottom)
Asp732 has c1 at160 and hydrogen bonds with
Gln536 (with c2 + c3 = 35) and potentially with
Ala734 also.
(C) Percentages of time when four ligand-protein
and intraprotein hydrogen bonds were formed in
two umbrella-sampling simulations, in which both
x1 and x2 were restrained at 10.0 or 10.5 A˚.
(D) Distributions of Asp732 c1 for the seven pro-
tein-ligand systems in these simulations.
See also Figure S2.
Structure
Free-Energy Surface and Partial Agonismbinds to the D1 lobe, the side chain of Asp732 stays in the 60
rotamer to form a strong interaction with the former’s amino
group, thereby stabilizing the cleft-closed conformations (Fig-
ure 5B, top). On the other hand, when an antagonist binds to
the D1 lobe, Asp732 switches to the 180 rotamer and stabi-
lizes the cleft-open conformations (Figure 5B, bottom). In the
GluA2 LBD, residue Lys730was proposed to act as a switch dur-
ing ligand binding (Armstrong andGouaux, 2000). Specifically, in
the apo form, Lys730 interacts with Glu705 (the counterpart of
GluN1 Asp732), but in the agonist-bound form, it switches to
interact with Asp728, thereby releasing Glu705 to interact with
the ligand’s amino group.
In a recent functional and computational study on LBD-
TMD linker insertion mutants of NMDA receptors, Kazi et al.
(2014) presented strong evidence for a mechanical pulling
model of channel opening. Our study further suggests that
the pulling force is generated by the ligand-bound LBD
behaving like an extended spring (Figure 6). The spring con-
stant is just the free-energy basin curvature. As the ligand
size is increased, the spring constant is reduced, thus gener-
ating a smaller pulling force and a reduced likelihood of chan-
nel opening. There is an opportunity to directly test this
refined mechanical model by the type of functional assays
of Kazi et al. (2014).
Whereas the LBDs in AMPA receptors largely respond to
ligand size through the degree of cleft closure (Armstrong and
Gouaux, 2000; Du¨rr et al., 2014; Jin et al., 2003), the response
of the GluN1 LBD is found here to be through the curvature of
free-energy surface. A correlation between ligand size and effi-
cacy was observed previously for AMPA receptors (Du et al.,Structure 23, 228–236, January 6, 20152012). This correlation can now be
extended to NMDA receptors (Figure 1B),
with the curvature of free-energy surface
apparently providing the mechanistic
link. The mechanistic difference mayexplain different manifestations of partial agonism at AMPA
and NMDA receptors at the single-channel level. AMPA recep-
tors possess subconductance states and partial agonism there
has been attributed to a population shift from states with higher
conductance to states with lower conductance (Jin et al., 2003;
Poon et al., 2010). In contrast, NMDA receptors have one
conductance state, and partial agonism there is thought to
reflect a decrease in open channel probability as opposed to
open channel conductance (Erreger et al., 2005; Kussius and Po-
pescu, 2009). We can speculate that, when a partial agonist
binds to AMPA receptors, it induces a graded cleft closure,
thereby shifting the population from high to low conductance
states. On the other hand, when a partial agonist binds to
NMDA receptors, it can produce full closure of the LBD cleft,
but also allows a certain probability for the LBD to sample con-
formations with a not fully closed cleft, leading to channel
closure.
The present study of the partial agonism at NMDA receptors is
limited to the cleft closure energetics of the GluN1 LBD mono-
mer. It should be noted, however, that channel activation in-
volves concerted actions of the different domains in the context
of a tetramer (Figure 6). Coupled motions of the LBDs and the
TMD tetramer and interactions between the four subunits can
all be expected to contribute to agonist efficacy. Still, we note
that the LBDs are the first responders to agonist binding. Other
domains would transmit, amplify, or attenuate the effects of
the agonist-induced LBD cleft closure, but the closure has to
occur in the first place. Also, given the modular architecture of
NMDA receptors, we speculate that at least some of our compu-
tational results on the GluN1 LBD, in particular the influence ofª2015 Elsevier Ltd All rights reserved 233
Figure 6. Mechanical Model of NMDA Receptors
For clarity, only two of the four subunits are shown. In each subunit, the LBD is modeled as an extended spring, which generates a pulling force on the LBD-TMD
linker. The TMD is also modeled as a spring (Fowler and Sansom, 2013). The spring constant of the LBD is given by the curvature of free-energy surface, and can
be reduced when the ligand size is increased (from left to right), leading to a smaller pulling force on the linker.
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Free-Energy Surface and Partial Agonismligand size on interlobe interactions, may apply to the full-length
tetramer context. Recently, the structures of the full-length
GluN1-GluN2 receptor have been determined (Karakas and Fur-
ukawa, 2014; Lee et al., 2014). When the GluN1 subunits are
bound with Gly (PDB 4PE5), the degree of LBD cleft closure
was nearly the same as in the isolated LBD (PDB 1PB7; Fig-
ure S2). In contrast, when bound with ACPC, which is larger
and a partial agonist, the GluN1 LBDs in the full-length receptor
(PDB 4TLM) were more open than in the isolated LBD (PDB
1Y20; Figure S2). The more-open structure may reflect ACPC-
induced weakening of interlobe interactions in the full-length
context.
Like the GluN1–3 subunits, a more distantly related iGluR (Av-
GluR1) has been found to have similar LBD structures when
bound with agonists spanning a range of efficacies (Lomash
et al., 2013). A similar observation can be made on the crystal
structures of b1-adrenergic receptor, a prototypic G-protein-
coupled receptor, bound with a full agonist and a partial agonist
(PDB 2Y02 and 2Y04) (Warne et al., 2011). It is tempting to hy-
pothesize that a reduced curvature of free-energy surface
contributes to the partial agonism at these receptors, and may
present a unique paradigm in producing graded responses for
receptors in general. Further experimental and computational
studies have to be done to test this hypothesis.
EXPERIMENTAL PROCEDURES
Ligand Parameterization
Structures of the seven ligands, Gly, DSN, DCS, ACPC, ACBC, CLE, and
DCKA, were obtained from the crystal structures of their complexes with the
GluN1 LBD (PDB entries 1PB7, 1PB8, 1PB9, 1Y20, 1Y1Z, 1Y1M, and 1PBQ,
respectively). Hydrogen atomswere added to the ligands using UCSFChimera
(Pettersen et al., 2004). Partial charges were obtained by fitting to molecular
electrostatic potentials from quantum chemistry calculations through the
R.E.D. server (Vanquelef et al., 2011), with the net charges of the first six li-
gands constrained to 0 and that of DCKA to –1. Other force field parameters
for the ligands were taken from the general Amber force field (Wang et al.,
2004).234 Structure 23, 228–236, January 6, 2015 ª2015 Elsevier Ltd All rigSimulations of the LBD-Gly Complex
The system was prepared using the tLeap tool of Amber 12 (Case et al., 2005),
and started from the crystal structure of the GluN1 LBD bound with Gly.
Missing residues (D441 to R448) on loop 1 were built using MODELER (Eswar
et al., 2006). A water box with a 10.75 A˚ buffer zone was used to solvate the
system. Crystal watermolecules were retained, and 37 sodium and 39 chloride
ions were added to neutralize the system.
All simulations were done in NAMD 2.9 (Phillips et al., 2005), using the Am-
ber99SB force field for the protein (Hornak et al., 2006). The solvated system
was first energy minimized for 5,000 steps with the protein Ca atoms fixed.
It was then gradually heated up to 310 K in 310 ps, and equilibrated for 1 ns,
while restraining the protein Ca atoms with a force constant of 1.0 kcal/mol/A˚2.
Subsequently, targeted molecular dynamics simulations were used to
generate various initial conformations, and simulationswith harmonic restraints
were used to carry out umbrella sampling. In both of these simulations, the sta-
ble bifurcate hydrogen bond between the a-carboxylate oxygens of the ligand
and the Nh1 and Nh2 atoms of Arg523 was maintained by restraining the two
interatomic distances, each with a one-sided flat-bottom harmonic potential
that started at a 3.0 A˚ distance and had a mild force constant of 2.0 kcal/mol/
A˚2. These restraints ensured that the ligand remained bound to the D1 lobe
(McFeeters and Oswald, 2002). In addition, the core regions of the D1 and D2
lobes were restrained to their conformations at the start of the targeted molec-
ular dynamics simulations, each by a one-sided flat-bottom harmonic potential
that started at a 1.0 A˚ Ca root-mean-square deviation and had a force constant
of 100kcal/mol/A˚2. TheD1core region consisted of residues Leu398 toGlu422,
Val431 to Gly438, Val451 to Thr486, Asn499 to Lys534, and Phe758 to Arg794,
whereas the D2 core region consisted of residues Leu538 to Thr748.
Two reaction coordinates were defined to describe interlobe relative motion
(Lau and Roux, 2007). The first, x1, is the distance between the Ca centers of
mass (COMs) of Leu517-Ile519 on D1 and Ser688-Val689 on D2; and the sec-
ond, x2, is the distance between the COMs of His404-Glu406 on D1 and
Ala714-Ala715 on D2. The targetedmolecular dynamics simulations consisted
of two phases. In phase 1, (x1, x2) were forced to gradually change from their
values, (8.6, 7.7), in the crystal structure first to (12.0, 12.5) during the
course of 5 ns and then to (16.0, 16.5) during the course of another 4 ns,
roughly along the diagonal line. In phase 2, off-diagonal positions were popu-
lated. Specifically, starting from a snapshot from phase 1, x1 was restrained at
each of 9.0, 9.5,., 15.5, 16.0 A˚ while x2 was forced to increase from an initial
value up to 16.5 A˚ (at a rate of 1.0 A˚/ns of simulation time) to cover one side of
the diagonal and then vice versa to cover the opposite side of the diagonal. In
total, 171 conformations were generated, with (x1, x2) values covering a 2D grid
at roughly a 0.5 A˚ spacing in each direction.hts reserved
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Free-Energy Surface and Partial AgonismIn the umbrella-sampling simulations, x1 and x2 were restrained to various
target values with a force constant of 10.0 kcal/mol/A˚2. Each restrained simu-
lation lasted 3 ns. The weighted histogram analysis method (Kumar et al.,
1992) was used to generate the free-energy surface from the distributions of
x1 and x2.
Simulations of the LBD Bound with Non-Gly Ligands
The last snapshots of the umbrella-sampling simulations in the Gly-bound
case were used to seed the umbrella-sampling simulations for the next larger
ligand, DCS. Specifically, Gly was replaced by DCS after superimposing five
corresponding backbone atoms of the two ligand molecules (i.e., CA, C, N,
O, and NG on DCS and CA, C, N, O, and OXT on Gly). The resulting solvated
LBD-DCS complex was energy minimized for 5,000 steps with the protein Ca
atoms fixed, and equilibrated for 400 ps while restraining protein Ca atoms
with a force constant of 1.0 kcal/mol/A˚2. The subsequent umbrella-sampling
simulations and data analysis were identical to those in the Gly-bound case.
This procedure of replacing a ligand with the next larger ligand was repeated
to calculate the free-energy surfaces for the remaining ligands. For the two an-
tagonists, which were larger in size, steric clashes were encountered in some
initial conformations after ligand replacement, and were relieved by manually
adjusting the ligand positions. For the DCKA-bound case, a water molecule
was randomly selected and replaced by a sodium ion to maintain charge
neutrality of the system. The 171 umbrella-sampling simulations for CLE
were uniformly extended to 6 ns, and no significant changes in the free-energy
surface were found.
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